Feasibility Study: Ulthera® System for the Treatment of Moderate to Severe Facial Acne

NCT ID: NCT01591304

Last Updated: 2017-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the effectiveness of Ultherapy for the treatment of facial acne.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study subjects will be assigned to one of two treatment groups. Both treatment groups will receive treatment in the center of the forehead/temples, medial cheeks, and chin regions using the 1.5mm and 1.0mm transducers.

* For Group A, both the 1.5mm and 1.0mm transducers will be used at 0.25J energy setting and 0.20J energy setting, respectively.
* For Group B, both the 1.5mm and 1.0mm transducers will be used at 0.18J energy setting and 0.15J energy setting, respectively.

Subjects will receive 3 Ultherapy treatments administered 2 weeks apart. Subjects will be required to return for follow-up assessments at 14, 30, 60, 90 and 180 days following the third Ultherapy treatment. Pre- and post-treatment photos will be taken. In addition, pre- and post-treatment lesion counts and sebum measurements will be obtained.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Facial Acne

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Ulthera® System Ultherapy™ Treatment Ulthera, Inc.

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Ulthera System Treatment provided using 1.5mm and 1.0mm transducers at 0.25J and 0.20J energy settings, respectively.

Group Type ACTIVE_COMPARATOR

Ulthera System Treatment

Intervention Type DEVICE

Focused ultrasound energy delivered below the surface of the skin.

Group B

Ulthera System Treatment provided using 1.5mm and 1.0mm transducers, at 0.18J and 0.15J energy settings, respectively.

Group Type ACTIVE_COMPARATOR

Ulthera System Treatment

Intervention Type DEVICE

Focused ultrasound energy delivered below the surface of the skin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ulthera System Treatment

Focused ultrasound energy delivered below the surface of the skin.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ulthera® System Ultherapy™ Treatment Ulthera, Inc.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female, aged 18 years and older.
* Subject in good health.
* Presence of clinically-evident facial acne of moderate to severe severity with at least 20 inflammatory lesions and 20-100 noninflammatory lesions.

Exclusion Criteria

* Presence of \>2 nodular lesions in the areas to be treated.
* Presence of any cysts in the areas to be treated.
* Presence of an active systemic or local skin disease that may affect wound healing.
* Use of alcohol-based topical solutions or "exfoliating" agents within 1 week prior to study participation.
* History of frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections.
* History of keloid scar formation.
* Significant scarring in areas to be treated.
* Significant open facial wounds or lesions.
* Presence of a metal stent or implant in the facial area to be treated.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ulthera, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Girish Munavalli, M.D.

Role: PRINCIPAL_INVESTIGATOR

Dermatology, Laser & Vein Specialists of the Carolinas

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Multispecialty Aesthetic Clinical Research Organization

Woodland Hills, California, United States

Site Status

Dermatology, Laser & Vein Specialists of the Carolinas

Charlotte, North Carolina, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ULT-116

Identifier Type: -

Identifier Source: org_study_id